Meeting
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
Authors
Gordon Taylor Moffat
Queen's University, Kingston, ON, Canada
Gordon Taylor Moffat , Weidong Kong , Christopher M. Booth , Josee-Lyne Ethier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5555)
DOI
10.1200/JCO.2022.40.16_suppl.5555
Abstract #
5555
Poster Bd #
434
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).
First Author: Martin R. Stockler
Poster
2022 ASCO Annual Meeting
PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.
First Author: Judith Michels
Poster
2022 ASCO Annual Meeting
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Thomas J. Herzog
Poster
2016 ASCO Annual Meeting
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
First Author: Beverly Long